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Abstract: Background: Zinc is an essential component for all living organisms, representing the second most 
abundant trace element, after iron. This element is widely distributed in the tissues of human body where it is 
involved in the normal growth, reproduction and several biological functions including immunity, energy 
metabolism and antioxidant processes. Because of its essential role, zinc levels in human body must remain 
constant, independently of dietary intake fluctuations. The homeostasis of zinc is a well-regulated cellular 
process and has been reported to be chiefly mediated by the expression and activity of zinc-binding proteins 
such as metallothioneins and zinc transporters. Genes encoding for these proteins are subjected to genetic 
variants. 
Methods: We performed a multi-database electronic search to provide an overview on the relationship 
between specific polymorphisms (SNP) of genes encoding for metallothioneins and zinc transporters and their 
relationship with zinc status, immune function and some non-communicable diseases. 
Results: A number of SNP are implicated in a range of metabolic disease. Some SNP may affect the impact 
of zinc supplementation on immune function, diabetes, obesity. 
Conclusion: New studies are needed to clarify the interaction between individual genetic profile and zinc 
status. Moreover, there is a need to a better interaction between the scientific bodies and health professionals to 
allow better dietary and behavioural recommendations to promote human health, with particular concern to 
elderly people.         
Keywords: Zinc, Genetic Polimorphisms, Metallothionein, Zinc transporters, Immune function, Non- 
communicable disease 
 
1. INTRODUCTION 
Zinc (Zn) is recognised as an essential 
micronutrient involved in the structural and 
functional components that underpin a wide range 
of biological processes involved in cellular 
metabolism, growth, development, cellular 
physiology and immune function [1]. To date more 
than 300 enzymes and 100 transcription factors 
have been identified to have a requirement of Zn 
for their activity. Zn plays a key role as a structural 
component for the stabilization of the tertiary 
structure of many proteins, such as  transcription 
factors containing "zinc finger" (ZNF) domains, 
which interact with a variety of proteins, lipids and 
nucleic acid. Moreover, as cofactor of numerous 
enzymes present in animal tissues, it ensures the 
catalytic activity of six main classes of enzymes 
including oxidoreductases, transferases, hydrolases, 
lyases, isomerases and ligases [2, 3].  
Because of its essential pleiotropic role, human 
body needs to maintain constant levels of zinc, 
independently of dietary intake fluctuations. In 
humans, the daily turnover corresponds to about 
1% of the total zinc content. Zinc is lost through 
urine and by the non-avoidable skin and intestinal 
cell desquamation and hair. In specific harsh 
conditions, significant amounts can be lost through 
perspirations and together with occasional loss of 
fluids during menstruations and ejaculation. The 
homeostasis is therefore obtained thanks to its daily 
replacement by the diet and is closely controlled by 
the intestinal absorption system and excretion 
through pancreatic and intestinal secretions. The 
homeostasis of zinc is a well-regulated cellular 
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process. In fact, the expression of the membrane 
conveyors and zinc sequestering proteins varies 
greatly and rapidly, depending on the intracellular 
concentration of zinc [4]. 
The homeostasis of zinc has been reported to 
be chiefly mediated through the expression and 
action of zinc binding proteins such as 
metallothioneins (MTs) and zinc transporters [5, 6]. 
According to membrane topology data, transporters 
of zinc have been grouped into two major families:  
(a) 10 zinc “exporters” (ZnT1-10) of the 
SLC305 family, which are associated with 
lowering of cytoplasmic zinc by transportation of 
zinc either out of the cell or into intracellular 
organelles, and  
(b) 14 zinc “importers” of the SLC39s family 
(Zrt (zinc regulated transporter)-like Irt (iron-
regulated transporter)-like proteins, ZIP 1-14), the 
activity of which result in increased cytoplasmic 
zinc [7].   
Zinc associated to enzymes and transcription 
factors accounts for about 90% of the zinc 
proteome – indicating the key role of this trace 
element in the regulation of the processes of 
catalysis and transcription [6]. MTs are a cysteine-
rich family of proteins, mainly localized at the level 
of Golgi apparatus having the capacity to bind 
either Zinc and other transition elements (Selenium 
and Copper) or potentially toxic heavy metals such 
as mercury and arsenic [8]. By binding and 
releasing zinc, MTs may regulate zinc levels within 
the body and are involved in Zn detoxification. 
Thanks to its protein sequence, rich in cysteines, 
and its quaternary structure, MTs are able to bind 7 
zinc atoms, sequestering them from the 
surrounding environment, in order to protect the 
cell from its toxic action [9]. MTs expression is 
ubiquitous but is particularly high in parenchymal 
cells of the intestine, pancreas, kidney and liver. 
Very few data are available on the molecular 
mechanisms involved in MTs’ and ZnTs’ 
functions. MTs’ cellular protection mechanisms 
were initially shown to involve interaction with 
antioxidant proteins [10-12]. Then, a role of 
reactive oxygen species (ROS) [13], anti-
inflammatory [14], antiapoptotic proteins [15] and 
of the mitogen-activated protein kinase [16] was 
reported. More recent findings show an indirect 
involvement of uncoupling proteins in the MTs-
dependent attenuation of the free radical-induced 
cardiac toxicity [17]. With respect to ZnTs, some 
data is available for ZnT7 that has been shown to 
upregulate insulin gene expression through MTF1 
activation [18] and Irs2 and Akt phosphorylation 
[19]. MTF1 is believed to act as a buffer 
influencing the cellular sensitivity to zinc through 
the modulation of MT and ZnT expression [20], 
however, no information is available on the 
relationships between ZnTs, zinc and MTF1. 
Similarly, ZnT9 functions as a transcriptional 
coactivator moving into the nucleus upon activation 
by hormone stimulation, binding to nuclear 
receptors complexes to regulate gene transcription 
[21] and activating Wnt signaling through β-catenin 
interaction [22]. However, no information is 
available on ZnT9 transcriptional activation.  
Zinc deficiency has been associated with 
insufficient dietary intakes or impaired intestinal 
function in groups of population either aged or 
suffering of a wide spectrum of different chronic 
conditions and also related to specific dietary 
profiles such as vegetarian/vegan [23,24]. Given 
that there are no specialised storage reserves of zinc 
within the body, it is necessary to maintain an 
adequate, regular supply [25]. Specifically, people 
in developing countries are at particular risk and it 
has been estimated that globally close to 2 billion 
people may be zinc deficient [3]. A broad range of 
clinical manifestations have been associated either 
to nutritional zinc deficiency or to inherited 
phenotypes concerning zinc absorption and 
metabolism. When zinc homeostasis is concerned, 
several important pathologies have been reported 
including growth retardation, testicular 
hypofunction, compromised immune function, 
oxidative stress, and an increase in the production 
of inflammatory cytokines [2, 5, 7, 26-28]. 
Accordingly with the evidence of the association 
between zinc deficiency or malnutrition and 
diarrheal disease, zinc supplementation has been 
used for the treatment and prevention of diarrhoea 
in infants and children [3,29]. The occurrence of a 
more marginal zinc deficiency has been observed 
in vegetarians and vegans and is thought to be the 
result of the consumption of high levels of zinc-
chelating agents present in cereals, legumes or 
plant parts. In fact, lignins and phytate, found in 
these types of foods, have been reported to be able 
to bind Zinc and counter its absorption therefore 
reducing its bioavailability [6, 30,31]. It has also 
been reported that a rise in Cu to Zn ratio (CZr) is a 
common feature associated with a number of age-
related chronic conditions; something which has 
been postulated to be more dependent on 
physiological alterations arising with age as 
opposed to regular nutritional intake [32,33]. 
Elderly people are a group of population at an 
increased risk of nutritional disorders owing to a 
combination of the impact of the ageing on 
physiological/physical/biochemical capacities, as 
well as behavioural and dietary factors [24,34]. 
People aged more than 60-65 years have been 
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reported to have intakes of zinc significantly below 
the recommended intakes, and about 30% of them 
has been assessed as “zinc deficient” [6].This 
deficiency, is likely to result in impaired immune 
function  and in a significant increase of the risk of 
a spectrum of degenerative disease [24]. 
Zinc has low toxicity and is generally 
considered to be safe even though very high, 
excessive supplementations can have detrimental 
consequences possibly due to inadequate 
absorption of copper [35]. Therefore, numerous 
zinc supplementation trials have shown a wide 
range of health benefits, including decrease 
diarrhoea mortality in children, incidence of 
infections and immune functions improvement [36-
39]. Moreover, the efficacy of zinc supplements in 
boosting health and well-being has been further 
confirmed by the meta-analysis addressing growth 
and body weight gain in children [40] and also 
dealing with the  incidence of blindness and the 
risk of developing age related macular degeneration 
[41].  
Single nucleotide polymorphisms (SNPs) are a 
common type of genetic variation with high 
prevalence (>1%) among people. Each SNP is 
characterized by a specific substitution of a single 
DNA base occurring with high frequency. Overall, 
population studies conducted by multicentric 
consortia have recent contributed to the 
identification of about 60 million SNPs in the 
human genome [42]. These allelic variants may fall 
within coding and in non-coding sequences of 
genes as well or in the intergenic regions (regions 
between genes). SNPs within a coding sequence do 
not necessarily change the amino acid sequence of 
the encoded protein due to degeneracy of the 
genetic code: in fact, synonymous SNPs do not 
affect the protein sequence.  SNPs not occurring in 
protein-coding regions may still affect gene 
splicing, transcription factor binding, messenger 
RNA degradation, or the sequence of noncoding 
RNA. SNPs may determine an individual’s 
response to certain drugs, and the susceptibility to 
environmental factors such as toxins, and risk of 
developing particular diseases. So far several SNPs 
have been associated with complex diseases such 
as heart disease, diabetes, and cancer. 
Several SNPs have been identified to modulate 
zinc intake/ status [43]. Costarelli e colleagues [44] 
have reported that gene expression of MTs, zinc-
transporters and inflammatory cytokines are 
regulated by zinc intake. In addition to zinc-
regulated transcription, genetic polymorphisms of 
MTs and zinc transporters have been associated 
with age-related diseases, such as chronic 
inflammation [45], type 2 diabetes ([46] and 
cardiovascular diseases (CVD) [47].  
In this review, we will focus on the relationship 
between specific polymorphisms of genes encoding 
for MTs and zinc transporters and their relationship 
with zinc status, immune function and some non- 
communicable diseases. 
 
2. GENETIC POLYMORPHISMS OF 
METALLOTHIONEINS AND ZINC 
TRANSPORTERS 
As mentioned above, the physiological 
requirement of trace metal elements is regulated by 
proteins specialized in the transport and deposit of 
metals in non-toxic forms. MTs have been very 
well characterized for their high content in 
cysteine, an amino acid that plays a key role in the 
formation of complexes with transition metals 
resulting in a high capacity to bind heavy metals 
[48]. At the same time, zinc transporters (ZnTs) 
family of membrane transport proteins of the solute 
carrier family control the membrane transport of 
zinc and regulate its intracellular and cytoplasmic 
concentrations [49,50]. ZnTs belong to two major 
groups: i) zinc transporters (ZnT) involved in the 
controls the efflux of zinc from the cytoplasm out 
of the cell and from the cytoplasm into vesicles; 
and ii) zinc importers, Zrt- and Irt-like protein 
(ZIP), controlling the influx of zinc into the 
cytoplasm from outside the cell and from vesicles 
[48,50]. 
SNPs in genes encoding for MTs and ZnTs can 
modify different aspects of gene product including 
its transcription, and also the specific molecular 
characteristics of the protein resulting e.g. in 
changes of their Zn binding affinity  [51,52].  
Such finding, already 20 years ago, encouraged 
for the search of genetic variants affecting the 
functioning of MTs and ZnTs, both necessary for 
cellular zinc homeostasis.   
2.1 Metallothioneins 
MTs can be considered “cellular buffer” of 
metals regulating their cellular amounts and being 
in turn regulated by metals, protecting organisms 
from harmful effects of highly toxic heavy metals, 
such as cadmium and mercury, but also regulating 
the cellular amounts of trace metal micronutrients 
including zinc, copper, iron, manganese. MT are 
low molecular weight (6-8 kDa) proteins with high 
content of cysteine, a low or null content of 
aromatic amino acids, and spectroscopic 
characteristics typical of metal-thiolate clusters. 
Cysteine content and its particular sequence 
arrangement is crucial for the MTs’ ability to form 
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complexes with heavy metal ions, those three-
dimensional structure is influenced in turn by 
presence of the metal [53]. MTs are particularly 
abundant in liver and kidney tissues and they are 
also present in the central nervous system and in 
mammary, olfactory and thyroid glands, in gastric 
and intestinal tissues, in hair follicles and in 
circulating monocytes.  
As mentioned above, the main role of MTs is 
linked to their ability to bind and regulate the 
homeostasis of essential trace elements, in order to 
prevent their harmful effects [54]. MTs are 
polymorphic genes, clustering together on a single 
chromosomal locus (16q12-22 for homo sapiens 
[55]), and coded proteins have very similar amino 
acid sequences. Accordingly, experiments on 
transgenic mice [56] suggested already 20 years 
ago that single MT isoforms are not essential for 
life but rather that MT functions are redundant and 
compensated by homeostatic mechanisms.  
Several studies have demonstrated that MT 
isoforms are differentially transcribed, translated 
and maintained in the cell, with a different response 
to metals. MT1 and MT2 isoforms, which are 
present in all mammalian tissues, are inducible, 
with MT2 appearing to be expressed more than 
MT1 [57], constituting the 50% of the total 
expressions of all metallothionein isoforms [58] 
and being frequently overexpressed in invasive 
human breast cancers [59]. 
2.1.1 MT polymorphisms   
2.1.1.1 MT1A polymorphisms 
According to the database of The National 
Center for Biotechnology Information (NCBI, 
http://www.ncbi.nlm.nih.gov/SNP/, May 2018), 98 
validated SNPs are present in the human MT1A 
gene region. Ten are located in the 5’UTR, 14 in 
the coding sequence, 64 in introns and 10 in the 
3’UTR (May 2018). Of these, seven SNPs are 
mentioned in the literature (rs11076161, 
rs8052394, rs7196890, rs11640851, rs7190725, 
rs11076160, rs8049883 and rs11647171) and three 
have an impact on metabolic disease [60, 61] (table 
1). rs11076161 and rs8052394 were considered in a 
search for an association between MT and type 2 
diabetes mellitus (T2DM) in a population of 851 
Chinese people of Han descent (397 diabetes and 
454 controls) [60]. An association of the SNPs was 
found with the disease and its clinical symptoms, 
i.e. neuropathy (rs11076161) and serum superoxide 
dismutase activity (rs8052394) [60].  
 
Table 1. MT polymorphisms, SNP variant and association with metabolic disease  
MT polymorphisms SNP variant Associated with Ref. 
MT1A     
rs11076161 intron Diabetic neuropathy [60] 
rs8052394 missense  T2DM, Serum superoxide dismutase [60] 
rs11640851 missense Longevity, Cardiovascular disease,  
T2DM, MT levels, IL-6 plasma concentration 
[61] 
MT1B     
rs964372 intron Hyperlipidemia, Diabetic neuropathy  [60] 
rs7198427 5’UTR Advanced glycation end-products [62] 
rs7197489 5’UTR Advanced glycation end-products [62] 
MT2A     
rs28366003 5’UTR CKD and DM 
B-MT and -Zn levels in T2DM 
[66] 
[46]  
rs1610216 5’UTR B-Zn levels, T1DM and cardiovascular 
complications 
Diabetes 
[45] 
 
[68] 
rs10636 3’UTR Atherosclerosis, B-Zn, B-Cu and inflammatory 
cytokines levels 
Diabetic neuropathy and hyperlipidemia in T2DM  
[69] 
 
[66] 
MT4     
rs396230 intron Blood pressure, serum uric acid [73] 
T2DM: Type 2 diabetes mellitus; CKD: chronic kidney disease; DM: diabetes mellitus; MT: Metallothionein; IL-6: 
Interleukin 6; T1DM: Type 1 diabetes mellitus. 
2.1.1.2 MT1B polymorphisms:  
103 SNPs are present in the human MT1B gene 
region. Seven are located in the 5’UTR, 25 in the 
coding sequence, 54 in introns and 17 in the 
3’UTR. Of these, nine SNPs are mentioned in the 
literature (rs964372, rs8052334, rs7191779, 
rs2070839, rs1875232, rs7197489, rs7198427, 
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rs12051311 and rs61744104) with the first four 
having a significant association with diseases. As 
for variants of MT1A, significant association of 
rs964372 exists with diabetic neuropathy (linked to 
hyperlipidemia) [60] (as for MT2A, see below). 
More recently, rs7198427 and rs7197489, initially 
attributed to the MT1A gene portion, were 
identified by genome-wide association study 
(GWAS) as associated to advanced glycation end-
products (AGEs) in diabetic subjects [62]. 
2.1.1.3 MT1E polymorphisms  
The MT1E gene regions contains 188 validated 
SNPs, ten are located in the 5’UTR, 63 in the 
coding sequence, 87 in introns and 28 in the 
3’UTR. Of these, only four SNPs are mentioned in 
the literature (rs7403881, rs34166523, rs2070836 
and rs708274) and an association of rs7403881 was 
reported with sporadic amyotrophic lateral sclerosis 
(SALS) [63]. None of these have been considered 
to be associated to metabolic disorders.  
2.1.1.4 MT1F polymorphisms 
112 SNPs have been identified so far in the 
human MT1F gene region. Eight are located in the 
5’UTR, 27 in the coding sequence, 51 in introns 
and 26 in the 3’UTR. Of these, only one SNP is 
mentioned in the literature (rs2291956) and still 
lacks any association with metabolic diseases. 
2.1.1.5 MT1G and MT1H polymorphisms  
A total of 258 validated SNPs have been found 
in human MT1G and MT1H gene regions, 
including 55 variants spread along all regions, but 
not in the 3’UTRs of the two genes, that bear 17 
and 11 SNPs respectively. Twenty 5’UTR SNPs 
are entirely shared between the two genes. SNPs in 
intron regions are discretely 94 and 78, plus 25 
shared. Finally, coding regions contain respectively 
27 and 26 SNPs, plus 10 shared variants. Of these, 
only five SNPs are mentioned in the literature for 
both genes, including two in shared gene regions 
(rs12448654 and rs4784708), and rs2298847, 
rs2298846 and rs12315 for MT1G and rs9934181, 
rs2062546 and rs2062545 for MT1H. None of 
these has been reported so far to have any 
association with metabolic diseases. 
2.1.1.6 MT1M polymorphisms 
MT1M variants, whose genomic region 
partially overlaps with that of the MT1JP 
pseudogene, include a total of 116 SNPs, 11 in the 
5’UTR, 34 in the coding sequence, 59 in introns, 
and 12 in the 3’UTR region. Five are mentioned in 
the literature, three with no associations with 
diseases (rs2270837, rs1827210 and rs1827208), 
and two linked with mercury levels in the urine 
(rs2270836) and in hair (rs9936741) [64]. 
Activation of MT1M in Hep-G2 cells, upon heavy 
metals or glucocorticoids exposition, was shown to 
affect NF-kB activity,  therefore potentially 
involving also metabolic dysfunctions [65]. 
2.1.1.7 MT1X polymorphisms 
139 SNPs have been already reported in the 
human MT1X gene region. Eleven are located in 
the 5’UTR, 21 in the coding sequence, 93 in introns 
and 14 in the 3’UTR. Of these, two SNPs are 
mentioned in the literature (rs2301234 and 
rs8051405) but none of them has been associated to 
metabolic diseases. 
2.1.1.8 MT2A polymorphisms 
According to the NCBI dbSNP database, the 
human MT2A gene region contains 68 validated 
SNPs. Eight are located in the 5’UTR, 14 in the 
coding sequence, 34 in introns and 8 in the 3’UTR. 
Among those, three SNPs are cited in the literature 
having association with diseases: rs28366003, 
rs1610216 and rs10636.  
Recently, the rs28366003 SNP has been 
associated with increased risk of chronic kidney 
disease (CKD), and diabetes mellitus (DM) in a 
large Japanese population [66],  
According to the previously reported 
association of MTs to diabetes and metabolic 
diseases [67], an association with the disease in 
elderly patients was reported with two more SNPs 
within MT2A. The first one, rs1610216, was linked 
to higher risk for type 1 diabetes mellitus (T1DM) 
and cardiovascular complications (chronic 
inflammation, higher plasma levels of IL-6 and 
glycosylated hemoglobin), together with lower 
plasma zinc levels, in Italian atherosclerotic 
patients [45]. rs1610216 has been confirmed to be 
associated to diabetes also in Bulgarian diabetic 
patients [68]. The second one, rs10636, was linked 
to higher risk of atherosclerosis and carotid 
plaques, increased inflammatory cytokines and 
decreased zinc and copper plasma levels [69]. 
rs10636 role in diabetes has been confirmed by 
Yang and coworkers that observed variants of the 
SNP in T2DM patients with diabetic neuropathy 
and hyperlipidemia [60]. 
2.1.1.9 MT3 polymorphisms 
The expression of MT3 (also known as growth 
inhibitory factor), is primary in the central nervous 
system [70]. According to the NCBI dbSNP 
database, the human MT3 gene contains 131 
validated SNPs. 26 are located in the 5’UTR, 22 in 
the coding sequence, 72 in introns and 11 in the 
3’UTR. Among those, three SNPs are cited in the 
literature and two (rs45570941 and rs11644094) 
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have been reported to be associated with distinct 
pathologies, but not to metabolic dysfunction.  
2.1.1.10 MT4 polymorphisms 
MT4 was isolated from digestive and neonatal skin 
epithelia [71] and showed better Cu binding 
properties than MT1 [72]. Two MT4 SNPs are 
present in the coding sequence and 55 in introns. 
Only one association has been reported, i.e. that of 
rs396230, with blood pressure and serum uric acid 
values in car battery workers [73]. 
 
2.2 ZnT zinc transporters 
ZnT are membrane proteins that regulate its 
intracellular and cytoplasmic concentrations of zinc 
through its transport. They differ from the zinc 
importers, Zrt- and Irt-like proteins (ZIP), because 
they control the efflux of zinc from the cytoplasm 
out of the cell (Znt1) and into vesicles (all other 
except ZnT9, considered a misnomer) [74], while 
the latter, not considered in this review, control the 
influx of zinc into the cytoplasm from outside the 
cell and from vesicles.  This review will not 
specifically address on ZIP and  will be mainly 
focus on  ZnT.  
The SLC30 family of ZnT zinc transporters 
family comprises 10 mammalian members that 
belong to the large superfamily of CDF transporters 
that also includes zinc transporters in bacteria, 
fungi, nematodes, insects and plants [75]. Based on 
structural information obtained in the bacterial 
homolog YiiP [76], CDF family members are 
predicted to have six trans-membrane domains 
(TM) and a histidine/serine-rich loop between TM4 
and TM5, except for ZnT5 which contains 
additional TM domains at the N-terminal. At the C-
terminal, ZnTsbear long tails, from 82 amino acids 
for ZnT7 to 203 for ZnT6. Differently from MTs, 
high length heterogeneity exists for the amino acid 
sequences upstream of the first TM domain where 
different subcellular targeting signals are present. 
Based on sequence similarities, ZnT family 
members are grouped into four subfamilies with 
SLC30A5 (ZnT5) and SLC30A7 (ZnT7) in 
subfamily I, SLC30A2/3/4 and SLC30A8 (ZnT2, 
ZnT3, ZnT4 and ZnT8) in subfamily II, SLC30A1 
(ZnT1) and SLC30A10 (ZnT10) in subfamily III, 
and SLC30A6 (ZnT6) and SLC30A9 (ZnT9) in 
subfamily IV.  
Expression of ZnT is in general ubiquitous 
(ZnT1) but ZnT5, ZnT6, ZnT7, and ZnT9 are 
highly expressed in certain districts and tissue-
specific with respect to other tissues and 
characterized by specific temporal patterns. For 
example, the members of the subfamily II are 
restricted to secretory tissues such as lactating 
mammary glands, glutamatergic neurons, prostate, 
and pancreatic β-cells. A high expression of ZnT5, 
ZnT6 and ZnT7 has been reported in the heart [77], 
in the brain [78] in the intestine [79], respectively 
while ZnT10 expression is limited to brain and 
liver [80].  
ZnT1 expression in the placenta and other 
tissues is induced by dietary zinc intake [81] and is 
switched on during post-implantation period in 
trophoblasts and in the maternal deciduum [82]. 
The activation depends on MTF1 binding to MRE 
of ZnT1 promoter [83]. On the other hand, dietary 
zinc intake reduces ZnT5 expression both in vitro 
in Caco2 cells and in vivo in the ileal mucosa [84].  
Differently from MT KO, ZnT silencing has 
serious consequences and ZnT KO is hardly 
compatible with life, indicating a crucial role of 
these transporters. For instance, ZnT1 KO mice are 
embryonically unviable because of impaired zinc 
transfer from the mother [85]. ZnT5 [86] and ZnT7 
[79] are localized on the membrane of the Golgi 
apparatus and in cytoplasmic vesicles. ZnT7 KO 
mice display poor growth, with decreased adiposity 
and insulin resistance [87]. Znt8 KO mice have an 
impaired insulin secretion and zinc-insulin crystals 
[88,89].  
2.2.2 ZnT polymorphisms 
2.2.2.1 ZnT1, ZnT4, ZnT5, ZnT6, ZnT7 and 
ZnT9 polymorphisms 
According to the NCBI database (May 2018), 
152 and 1482 validated SNPs are present in the 
human ZnT1 and ZnT4 gene regions, respectively. 
With respect to ZnT1, four are located in the 
5’UTR, 93 in the coding sequence, 49 in introns 
and 4 in the 3’UTR. Regarding ZnT4, 109 are 
located in the 5’UTR, 90 in the coding sequence, 
1256 in introns and 27 in the 3’UTR.  
1527 SNPs are present in the ZnT5 gene region, 
14 in the 5’UTR, 172 in the coding, 1265 in introns 
and 76 in the 3’UTR. Among those, only two SNPs 
have publications in PubMed, rs337253 and 
rs164578, with no association with diseases. 
However,  rs337253 has been proposed to be 
associated with the expression of antioxidant 
response element (ARE)-regulated genes, and in 
particular to NRF2-mediated antioxidant response 
pathway [90], which is involved in metabolic 
diseases [91].  
Near three thousand SNPs have been identified 
in the ZnT6 gene region, 99 in the 5’UTR, 173 in 
the coding, 2309 in introns and 217 in the 3’UTR. 
Finally, almost four thousand SNPs are present in 
both Znt7 and Znt9 gene regions. Znt7 has 45 in 
the 5’UTR, 133 in the coding, 3292 in introns and 
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267 in the 3’UTR. Similarly, the majority of ZNT9 
SNPs are in the intron region (3496), 11 are located 
in the 5’UTR, 129 in the coding sequence and 43 in 
the 3’UTR. Several links are present for these three 
SNPs in PubMed citations, but no associations with 
metabolic diseases have been reported, so far. 
 
 
2.2.2.2 ZnT2 polymorphisms 
The human ZnT2 gene region presents 422 
SNPs. Eighteen are located in the 5’UTR, 107 in 
the coding sequence, 256 in introns and 41 in the 
3’UTR (May 2018). Several are mentioned in the 
literature and the number is actually underestimated 
because of the presence of rs-unclassified variants 
(table 2). So far, no association with metabolic 
disease has been reported.  
 
Table 2. ZnT polymorphisms, SNP variant and association with metabolic disease 
ZnT polymorphisms SNP variant Associated with Ref. 
ZnT2    
rs35623192 missense R340C T2DM (100) 
rs35235055 missense L23P T2DM (100) 
Znt8     
rs13266634 missense R325W T2DM 
T2DM drug therapeutic efficacy 
Proinsulin conversion 
Insulin secretion 
T1DM 
Dyslipidemia 
Chronic coronary artery disease 
Muscle strength and size 
[94- 96, 103-110] 
[105] 
[120-121] 
[122-123] 
[125-127] 
[129] 
[128] 
[130] 
rs16889462 missense R325Q T2DM and drug therapeutic efficacy [105] 
rs11558471 3’UTR T2DM [131-135] 
rs3802177 3’UTR T2DM [98,132,136] 
rs2466293 3’UTR T2DM 
T1DM 
Gestational diabetes mellitus 
[137] 
[138] 
[139] 
T2DM: Type 2 diabetes mellitus; T1DM: Type 1 diabetes mellitus 
 
2.2.2.3 ZnT3 polymorphisms  
According to the NCBI database, 1103 
validated SNPs are present in the human ZnT3 
gene region. 127 are located in the 5’UTR, 178 in 
the coding, 759 in introns and 39 in the 3’UTR. 
Several ZnT3 SNPs have PubMed links in 
neurological disorders and with Zn status, which is 
consistent with the phenotype of the mouse KO 
[92], but none was associated to metabolic disease 
or diabetes.  
2.2.2.4 ZnT8 polymorphisms 
According to the NCBI database more than 
eight thousand validated SNPs are present in the 
human ZnT8 gene regions, the majority are in the 
intron region (8021), 56 are located in the 5’UTR, 
141 in the coding sequence and 134 in the 3’UTR. 
32 SNPs have links with PubMed citations, and six 
have an association with diseases.  
rs13266634 has a number of citations (more 
than two hundred) related to the R325W variant, a 
well-known susceptibility locus of T2DM, since its 
finding ten years ago in several genome-wide 
association studies conducted in European [93-96], 
Asian [97-107], Russian [108], Tunisian [109], 
Mexican Mestizo [110] (but not Mexican 
[111,112], African [113], Hispanic American 
[114], Qatari [115] nor south Iranian [116]) 
subjects (reviewed in [117,118]. These findings are 
consistent with ZnT8’s major role as transporter of 
zinc, necessary for insulin maturation, into 
secretory pancreatic -cells [119]. In fact, impaired 
proinsulin conversion [120,121] and insulin 
secretion [122,123] have been found in carriers of 
the R325W variant. Recent reports demonstrate that 
T2DM risk depends on different zinc transport 
kinetics of the variants [124]. Because of its role in 
-cell functions, rs13266634 SNP was tested and 
found implicated also in T1DM [125-127], and in 
cardiovascular diseases incidence [128]. Other 
studies of associations of rs13266634 variants 
include implication with dyslipidemia in 
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HIV/hepatitis C virus co-infected patients [129] 
and with skeletal muscle strength and size [130]. 
Other ZnT8 SNPs implicated in T2DM were 
reported (frequently in high linkage disequilibrium 
with rs13266634), i.e rs16889462 [105], 
rs11558471 [131-135] and rs3802177 [98,132,136] 
and rs2466293 [137]. rs16889462, actually 
concerning the same codon 325 (R325Q) involved in 
rs13266634, found in a single African-Americans 
family, but not in Caucasians, was associated like 
rs13266634 with repaglinide therapeutic efficacy in 
Chinese patients [105]. rs2466293 has been 
recently associated with T1DM in Latin Americans 
[138] and was identified by means of in silico as a 
miR-binding SNP in Chinese pregnant women 
affected by  gestational diabetes mellitus (GDM) 
[139]. On the other hand, rs13266634 lowered 
GDM risk in in European women [140] and was 
excluded as a risk factor for Euro-Brazilian ones 
[141]. 
2.2.2.5 ZnT10 polymorphisms 
According to the NCBI database, the human 
ZnT10 gene region contains 1799 validated SNPs. 
50 are located in the 5’UTR, 125 in the coding 
sequence, 1571 in introns and 53 in the 3’UTR. 
Among those, six intron SNPs are cited in the 
literature to be associated with metal physiology 
but no reports about any association with metabolic 
syndrome has been reported.  
 
3. GENETIC POLYMORPHISMS, ZINC 
STATUS AND ALTERATIONS IN 
IMMUNE AND INFLAMMATORY 
FUNCTION 
Zinc has been demonstrated to have both 
antioxidant and anti-inflammatory roles. It has been 
described as a “second messenger” for immune 
cells, with a range of transcription factors 
associated with the gene expression of 
inflammatory cytokines and with adhesion 
molecules having been reported to be zinc 
dependent  [3]. Zinc has been demonstrated to have 
a role in both innate and adaptive immune function 
[23] with a long established relationship recognised 
between zinc deficiency and immune dysfunction 
[142]. Via its availability, which is closely 
regulated by a number of transporters and 
regulators, zinc functions as a modulator of 
immune response. Perturbations of these processes 
may alter zinc availability, impacting on the 
survival, proliferation and maturation of cells 
associated with both innate and adaptive immunity 
[143]. 
Patients who are clinically zinc deficient may 
present range of immune-related symptoms 
including lymphopenia, decreased ratio of T-helper  
(Th) cells to cytotoxic T-cells; a decrease in the 
cellular natural killer cell activity and an increase in 
cytoxicity. Such deficiency is associated with 
chronic diarrhoea, administration of parenteral 
nutrition lacking in zinc or as a result of excessive 
consumption of alcohol, as well as being found in 
patients with the malabsorption disorder, 
Acrodermatitis Enteropathica (AE). Owing to the 
prevalence of marginal zinc deficiency in older 
people there is likely to be a correlation between 
zinc status and impaired immune function in 
elderly people. Increased risk of inflammatory 
conditions, increased susceptibility to infection, 
autoimmune diseases, cardiovascular disease and 
cancer are all associated with immunosenescence – 
the age-related alterations in immune function [6, 
24, 36].  
Changes in immune function associated with 
zinc deficiency and ageing show many similar 
features in both innate and adaptive immunity and 
neutrophil function which led [24] to propose the 
existence of a tight relationship between zinc 
deficiency and immunosenescence. Zinc 
supplementation may, therefore, be particularly 
relevant in older people in the prevention, reduction 
or delay of disease. However, the data from 
intervention studies to date are conflicting. This 
may be owing to the usage of different doses, 
durations and forms of zinc supplements utilised. In 
addition in the presence of high oxidative stress 
high doses of zinc may trigger apoptosis of immune 
cells [144] The accumulation of zinc may reach 
toxic levels resulting in the aberrant activation of 
zinc-dependent enzymes such as PARP-1 with a 
role in genomic stability or promote the uptake of 
excessive levels of calcium into the cells, resulting 
in cell death [24]  
It has been stated that the key factors 
underpinning intracellular zinc levels during ageing 
are increased expression of MTs and defective zinc 
transporters, leading to increased sequestration of 
zinc and low intracellular free zinc content [145]. 
In its role as a “second messenger” within the 
immune system, zinc may alter the signalling 
cascades that promote antioxidant and immune 
defence [146]. In the elderly low free zinc ion 
availability and increased MTs levels may result in 
compromised antioxidant and immune response, 
increasing inflammation accompanied by repeated 
infections and risk of degenerative disease [145]. 
Although data from intervention studies are 
contradictory, there is evidence that zinc 
supplementation may have a positive impact on 
DNA repair and increase the expression of some 
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zinc transporters genes, improving zinc 
homeostasis and reducing infections [145,147,148]. 
Following a systematic review of the literature 
examining the relationship between zinc status and 
autoimmunity Sanna and coworkers [149] have 
identified a relationship between zinc homeostasis 
imbalance and the state of autoimmunity, 
suggesting a need to commence a screening 
campaign for the evaluation of zinc levels in 
children. They have also proposed a clinical trial in 
populations at higher risk of autoimmunity to 
investigate the possibility of personalised zinc 
supplementation for the prevention or treatment of 
autoimmune diseases.  
Giacconi et al. [47] reviewed the pro-
inflammatory genetic factors and zinc status in 
older atherosclerotic subjects and stated that the 
identification of polymorphisms of pro-and anti-
inflammatory cytokines and their interaction with 
nutrients, such as zinc that impact on Th1/Th2 
balance, represents an opportunity for predicting 
atherosclerotic plaque formation and targets for 
future therapies. Nonetheless, conflicting data exist 
between polymorphisms, the occurrence of 
atherosclerosis and the influence on zinc 
homeostasis.   
Genetic make-up may influence the response to 
zinc supplementation, with recent studies indicating 
that polymorphisms in IL-6-174 G/C and MT1a 
+647A/C loci may affect the impact of zinc 
supplementation on antioxidant and immune 
function in older people [24, 150,151]. In the rare, 
inborn disorder of zinc metabolism, AE, a mutation 
in ZIP 4 (SLC 49A4) importer gene results in 
severe zinc deficiency symptoms [152]. A variety 
of other polymorphisms in zinc-related proteins 
have been implicated in a range of disorders and it 
has been suggested that zinc, via zinc transporters, 
may affect DNA stability resulting in altered zinc 
homeostasis and metabolism [43]. Through zinc 
fingers, extraction part of several transcription 
factors, zinc is involved in the DNA replication 
processes which are necessary for a wide range of 
key cellular processes [145]. Some of these are 
transcription factors which are involved in the 
regulation of pro-inflammatory cytokines (IL6 and 
TNFα) and heat shock proteins (Hsp70) [153] 
Giacconi et al. [154] investigated the 
association of Hsp70 1267 A/G and TNFα -308 
G/A polymorphisms with pro-inflammatory 
mediators and zinc status in elderly people. 
Utilizing a linear regression modelling approach to 
examine additive, dominant or recessive 
associations of each SNP with pro-inflammatory 
mediators, MT and zinc status measures they 
concluded that HsP70 A/G is linked to the 
production of pro-inflammatory cytokines in 
healthy elderly people, which might be involved in 
determining how vulnerable individuals are to 
inflammatory disease. They also concluded that 
TNFα -308 G/A SNP do not impact on production 
of pro-inflammatory cytokines but that both SNP 
are associated with levels of creatinine. Giacconi 
and colleagues [52] also investigated the role of 
ZIP 2 Gln/Arg/Leu (rs2234632) polymorphism on 
zinc homeostasis and inflammatory response 
following zinc supplementation, again in elderly 
volunteers. Enhanced IL-6, TNFα and RANTES 
plasma level were demonstrated in ZIP2 Leu- 
(Arg43Arg) carriers. This was associated with 
decreased free cytosolic zinc and an up-regulation 
of the ZIP2, ZIP8 and Znt1 transporters. Upon zinc 
supplementation, the volunteers who were Leu- 
showed a decrease in inflammatory mediators. 
Wong et al.[155] investigated the impact of 
zinc deficiency on cellular immune activation and 
the epigenetic mechanisms which might enhance 
inflammation. They concluded that the zinc 
deficiency induced inflammatory responses at least 
partly by promoting irregular immune cell 
activation and altering promoter methylation.  
Borghaei et al. [156] demonstrated that the 
zinc-binding protein -89 (ZIP-89) cooperates with 
NF-kB to regulate matrix metalloproteins (MMPs) 
expression as a response to inflammatory cytokine. 
MMPs have important roles in physiological tissue 
remodelling and wound healing as well as roles in 
the pathology of a range of disease conditions and 
transcriptional mechanisms are key in regulating 
healthy physiological level. ZBP-89 has been 
reported to bind the MMP-3 promoter at a site 
which is polymorphic, namely 5A/6A along with 
NF-kB. Tissue MMP-3 protein levels are affected 
by this polymorphism. They reported that ZBP-89 
was necessary for maximal induction of both genes 
by IL-B and TNFα and suggested a role for ZBP-89 
in expression of MMP-1 and in inflammatory 
processes via interaction with NF-kB [156,157]. In 
2010 Mocchegiani et al. [158] reported that the 
contradictory data from studies investigating the 
association between IL-6 polymorphisms, 
longevity and age-related diseases appear to be as a 
result of the interaction of these inflammatory 
processes with dietary intake, providing further 
evidence for a link among gene interaction and 
frailty in older age. Mocchegiani et al. [145] 
provide further supporting evidence of 
micronutrient-gene interactions related to 
inflammatory/immune response and antioxidant 
activity in ageing and propose that elucidating 
these associations could give a formula of 
personalised zinc supplementation or chelation to 
promote healthy ageing and long life.    
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4. GENETIC POLYMORPHISMS 
INVOLVED IN ZINC STATUS AND NON 
COMMUNICABLE DISEASE 
Noncommunicable diseases (NCDs), also 
known as chronic diseases are the result of a 
combination of genetic, physiological, 
environmental and behaviours factors. The main 
types of NCDs are cardiovascular diseases, 
metabolic disorders, cancers and chronic 
respiratory diseases [159]. The metabolic disorder 
frequently known as the “metabolic syndrome” 
(MetS), is defined by a clustering of abdominal 
obesity, high level in serum concentration of 
triglycerides, a lower quantity level of 
high-density lipoprotein (HDL) cholesterol, high 
blood pressure and an increased fasting blood 
glucose level [160,161] .  
In Europe the MetS prevalence is 
approximately 25% of adults, with a progressive 
increase in the elderly population [162]. Moreover, 
the heritability for MetS ranges from 10% to 30% 
[163,164]. Meta-analyses revealed a combined 
heritability estimate for Adult Treatment Panel-III 
MetS of 0.24 (95% CI, 0.11-0.36) and for the 
MetS severity score of 0.50 (95% CI, -0.05 to 
0.99) [165], indicating that this syndrome is in part 
inheritable. Knowledge of the exact genetic factors 
underlying MetS development may help to explain 
why the features of MetS frequently co-occur 
within one individual [166]. 
Several studies have demonstrated a 
relationship between obesity and Zn homeostasis. 
In particular, a significant decrease of blood Zn 
levels and an increase of urinary concentrations 
have been found in obese patients [167-169]. 
Moreover, erythrocyte Zn levels have been found 
to be associated with BMI and waist 
circumference [170].  In obesity, low nutritional 
Zn status is also associated with the aggravation of 
obesity-related metabolic disturbances such as 
insulin resistance, inflammation, and altered lipid 
profile [44, 171] and numerous studies dealing 
with zinc supplementation reported an 
improvement of blood pressure, glucose, and LDL 
cholesterol serum level [172]. Zinc plays a role in 
insulin signal transduction through the modulation 
of insulin receptor phosphorylation and of the 
activities of phosphoinositide-3-kinase, 
phosphoinositide-dependent kinase 1, Akt/protein 
kinase B and glycogen synthase kinase 3, which 
are part of the insulin signaling pathway [173].  
The interaction between zinc status, obesity, 
altered glucose metabolism and other metabolic 
disorders may be at least partially mediated by the 
pathological-induced modulation of zinc 
transporters that regulate cellular and intracellular 
Zn fluxes [174]. 
In recent years, polymorphisms in the solute 
carrier family 30 member 8 (SLC30A8) gene 
(ZnT8) with increased type 1 [175-180] and type 2 
diabetes  [177, 181-184] susceptibility were found 
(see also paragraph 2). In fact, a connection 
between the functionality of SLC30A8 has been 
observed and zinc concentration in plasma was 
shown able to influence glucose tolerance [185]. 
Type 1 diabetes is characterized by a 
destruction of pancreatic β-cells, resulting in 
absolute insulin deficiency causing hyperglycemia 
through the involvement of autoimmune-
mechanisms and genetic and environmental 
factors, that can accelerate or slow down the 
clinical course of the disease [179].  The 
mechanisms involved in the autoimmune reaction 
against specific antigens of the pancreatic islands 
may involve ZnT8 which has been identified as a 
new target of cell mediated and humoral 
autoimmunity in T1DM [186]. The C allele of the 
rs13266634 SNP was found associated with 
younger age onset of T1DM patients [176] but not 
in a Swedish population [187].  Furthermore, 
Swedish subjects had a lower frequency of the 
R325 (C/C) genotype than the non-Swedes, which 
could reduce genetic predisposition to T1DM 
[186]. While rs11203203 was identified as a 
genetic marker in children, AA genotype conferred 
a higher risk of persistent islet autoimmunity and 
type 1 diabetes [188].  Both SLC30A8 
polymorphisms were found to be associated with 
the HLA-DQ gene. However, further research will 
serve to better understand the role of SLC30A in 
the pathogenesis of type 1 diabetes across different 
population and its association with other genes and 
HLA which may permit major advances in future 
diagnostic and therapeutic approaches. 
Type 2 diabetes is a progressive and chronic 
metabolic disease and it is characterized by 
peripheral insulin resistance and pancreatic beta β 
cell dysfunction with a growing interest in the role 
of zinc signaling in this disease [173,189].  GWAS 
of the past decade have identified variants in the 
human SLC30A8 gene as affecting the risk of Type 
2 Diabetes [189]. Genome-wide association studies 
demonstrate an association of the above mentioned 
rs13266634 SNP of ZnT8 with decreased insulin 
release and T2DM susceptibility [43]. In particular, 
the common allele C of rs13266634 was associated 
with increased odds of T2DM in Europeans and 
Asians populations [186]. However, when Zn 
intake was taken into consideration, the C allele of 
rs13266634 was associated with lower odds of 
T2DM after zinc supplementation [182]. On the 
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other hand, Maruthur et al [190] reported that 
carriers of the T allele have increased insulin 
response after supplementation with Zn and thus 
may benefit more from Zn supplementation. A 
recent study identified 44 novel SLC30A8 variants; 
the minor alleles of rs2464591, rs2466296, 
rs2466297, and rs2466299 were associated with 
improvement in β-cell function, while carriers of 
the minor allele of rs2466293 had worsened 
functions. However, no association was observed 
between Zn intake and SNPs on diabetes incidence 
suggesting a limited role for dietary manipulation 
in affecting risk in relation to the SNPs identified 
[191]. 
As systematically reported in paragraph 2, there is 
another common SNP rs11558471 A/G in 3’-UTR 
of the SLC30A8 gene. A cross-sectional meta-
analysis on 14 cohorts assessed the interaction of 
20 genetic variants known to be related to glucose 
metabolism traits among individuals of European 
ancestry [192]. The strongest interaction effect was 
detected for rs11558471, where carriers of the A 
allele had increased fasting glucose.  Moreover, a 
strong linkage disequilibrium between rs11558471 
and rs13266634 was observed in this study. The 
results show that an increase in Zn intake decreases 
diabetes risk in A allele carriers, suggesting that Zn 
intake has an inverse association with fasting 
glucose plasma concentration.  
All these observations highlight the need to 
generate personalized recommendations of Zn 
according to the genotype of SLC30A8 [43]. 
Similar results were also found in the Asian 
population [193-195]. In this population, another 
SNP (rs3802177) has been identified in the 
SLC30A8 gene which increases the risk of type 2 
diabetes [196]. Rs3802177 showed the strongest 
association with T2D compared to the other SNP 
in the SLC30A8 gene [194]. Moreover, this SNP is 
strongly linked (r2 = 0.83) to another SNP in the 
SLC30A8 gene, rs13266634 [196]. However only 
about 10% of the total hereditary risk of T2D can 
be attributed to SLC30A8 genes and this lack 
could be due to rare variants and epigenetic factors 
[197]. Flannick et al. [198] genotyped ~ 150,000 
individuals across five ethnicities and identified 12 
rare protein-truncating variants in SLC30A8 that 
overall have reduced risk of T2DM for over 60%. 
Of the 12 variants, two common protein-truncating 
variants (p.Arg138X and p.Lys34SerfsX50) were 
associated with T2DM protection. The association 
of common alleles of SLC30A8 polymorphisms 
with T2DM implicates that this is a susceptibility 
gene in T2DM, while loss of SLC30A8 function 
may have a protective effect in the diseases. With 
regard to epigenetics, a significant increase in 
DNA methylation levels in the SLC30A8 gene has 
been recently observed in patients with T2DM 
[197]. 
Independently of SNPs located within genes 
encoding for proteins involved in Zn metabolism 
and trafficking, allelic variants located in the gene 
region encoding for the zinc finger of transcription 
factors have been reported to play an important 
role in determining the genetic risk of metabolic 
disease. Among genetic polymorphisms involved 
in lipid metabolism and hypertension and 
associated with zinc, there is rs964184 within 
the Zinc Finger Protein 259 (ZNF259). Mirhafez 
and coworkers [199], in a study performed in an 
Iranian population, found that the risk of MetS is 
increased in individuals carrying the G allele with 
an OR of 2.52 (95% CI= 1.33- 4.77; P= 0.005). 
Likewise, others authors found a positive 
association between ZNF259 and serum lipid 
levels in different populations [200,201]. Wu et al. 
[202], performed a case-control study on 1,812 
MetS patients and 2,036 controls from the 
Northeastern of China and found significant 
differences (p < 0.05) between the two population 
groups within the ZNF259 rs964184 and 
rs2075290 genotypes,  that could thus be 
associated with triglycerides levels, blood 
pressure, abdominal obesity, fasting 
hyperglycemia and HDL-C levels.  Similar results 
were found by Ueyama et al. [203] on an Japanese 
population including 1,822 subjects with MetS and 
1,096 controls. A GWAS performed on 815 
Hispanic children seeking genetic markers 
associated with obesity-related traits identified 
among several genes involved in obesity 
pathogenesis also variants in the APOA5-ZNF259 
region, in particular linked with triglycerides 
levels (p = 2.5-4.8E-08)  [204]. 
 
5. CONCLUSIONS 
A constant daily supply of Zn is necessary to 
maintain an optimal nutritional status and health. 
Both zinc deficiency and excess may lead to 
important health impairment such as in immune 
function, cardiovascular diseases, type 2 diabetes. 
Zinc homeostasis is therefore critical to protect 
against infection and reduce the risk of 
inflammatory disease and other chronic 
pathological conditions. There is a growing body of 
evidence demonstrating links between the genetic 
factors and requirements for zinc and the 
consequential impact on immune function and 
other aspects of human health, especially and 
critically in ageing. 
Zinc homeostasis is mediated by 
metallothioneins (MTs) and zinc transporters. Zinc 
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status and specific polymorphisms of genes coding 
for zinc-transporters have been in fact associated 
with chronic diseases. Base mutation experiments 
have demonstrated that specific DNA mutations 
can modify the structure and the expression of MTs 
and affect their ability to bind metal, through the 
impairment of transcription factors’ activity to 
MTs’ regulatory elements [51]. Indeed, as here 
summarized, SNPs affect several MTs functions 
linked to metal binding, from cancer to metabolic 
syndrome-related pathologies and their 
complications. Overall, 18 MT SNPs with an 
impact on pathological processes are known and 16 
are in non-coding regions. They are present in 
every MT gene class, excluding 3 out 8 MT1 genes 
(E, F, G and H) though 12 SNPs occur in this class. 
Main implications are on metal disbalance (8 
SNPs) and cancer (6 SNPs). Metal-related 
functions are also impaired by specific SNPs in 
ZnT genes and a total of 28 SNPs are involved in 
pathological processes. Their effects include insulin 
levels [120-123] and severe complications like 
dyslipidemia  and diabetes [94-110,125-127, 131-
139]. However, differently from MT SNPs, the 
majority of ZnT variants involves non-synonymous 
changes in the coding region of genes (16 out of 
28). Variants belong mainly to ZnT2 and ZnT8 
genes, according to genes’ roles in insulin secretion 
[88,89]. Nonetheless, like for MTs, other functions, 
linked to cardiovascular [128], are impaired.  
New studies are needed to allow a more 
comprehensive understanding of MT and ZnT 
mechanisms of action and of the effects of their 
common genetic variants. Moreover, the clear 
impact of zinc in diseases strengthens the need of 
more studies in transporters’ role in the regulation 
of physiological processes, for the set-up of 
accurate biomarkers able to monitor and detect 
subtle changes in cellular zinc homeostasis. 
Genetic studies have demonstrated that common 
DNA polymorphisms in some metallothioneins and 
zinc transporters confer susceptibility for some 
chronic diseases but the information is still limited 
and there is a need to better clarify the interactions 
between genes and other molecules. Furthermore, 
when considering the assumption of Zn the results 
remain controversial. This highlights the 
importance in the near future to clarify gene-
nutrient interactions and provide a clear 
understanding of any intervention requirements. 
There is a need to communicate this scientific 
information to health professionals in a way, which 
will allow them to translate this into dietary and 
behavioural recommendations which will promote 
human health, particularly for the elderly.         
 
LIST OF ABBREVIATIONS (not included in the 
text) 
Irs2 = insulin receptor substrate   
Akt  = Protein kinase B (PKB),  
kDa = kilodalton 
UTR  = Untranslated region 
CDF  =  Cation Diffusion Facilitator  
NF-κB  =nuclear factor kappa-light-chain-
enhancer of activated B cells 
IL-6 =  Interleukin 6 
NCBI  = National Center for Biotechnology 
Information 
MRE = Metal response element 
KO mice =knockout 
NRF2  = Nuclear factor E2-related factor 2 
PARP-1 = Poly (ADP-ribose) polymerase-1  
HSP70  = Heat Shock Protein 70 kilodaltons 
TNFα = Tumor necrosis factor alpha 
RANTES  = Regulated on activation, normal T-cell 
expressed, and secreted 
APOA5 = Apolipoprotein A5  
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